Antitrust M&A
Weil has an impressive track record of obtaining global antitrust clearance in “bet-the-company” mergers, acquisitions and joint ventures, oftentimes in highly complex matters and industries facing heightened scrutiny.
We have extensive experience with the key global antitrust agencies including the U.S. Federal Trade Commission, the U.S. Department of Justice, the European Commission, and the UK Competition and Markets Authority. Our team includes a number of former senior U.S. and European government officials in our ranks. This deep bench and expertise gives us unmatched insight into how merger cases are analyzed, investigated, and litigated. We bring this perspective to bear in devising creative and successful deal strategies to minimize risks and delays for our clients, from initial risk assessment through to clearance.
As a result, Weil has an unparalleled track record of:
- Winning agency merger court challenges in U.S. courts.
- Leading the way on getting complex Phase 1 remedies cases over the line where, in recent times, we have consistently represented the merging parties on Phase 1 remedies cases approved by the EC.
- Advising on the most significant Phase 2 cases and securing clearance via innovative and ambitious remedies proposals, including the first UK fast-track Phase 2 remedies case that the CMA has approved since the procedure’s introduction in 2021.
Weil is consistently trusted by clients to handle multi-jurisdictional merger reviews and ensure swift approvals, with expert lawyers located in the United States and throughout Europe. In countries where Weil does not have offices, we have developed collaborative relationships with the best local law firms to ensure best-in-class service and an efficient process no matter the jurisdiction.
We also have significant expertise in the rapidly evolving foreign direct investment controls globally. We are trusted by clients to assess and successfully address the shifting regulatory risks associated with their cross-border investments, and to provide an efficient and transparent single point of contact for handling foreign investment control and merger control filings.
Client Recognition
50
Select Representations
Johnson & Johnson
Weil has successfully represented Johnson & Johnson in numerous multi-billion dollar transactions including, most recently, its ~$13.1 billion acquisition of Shockwave Medical Inc. and in its $1.7 billion acquisition of V-Wave.
Meta Platforms
Microsoft
Weil represented Microsoft in its $7.5 billion acquisition of global video game publisher, ZeniMax Media, Inc., parent company of Bethesda Softworks and other game studios and in its $68.7 billion acquisition of video game publisher, Activision Blizzard, the largest gaming deal in history.
Weil is representing Microsoft on the merger control aspects of its investment in OpenAI.
The Home Depot
Virgin Media O2
Cedar Fair
Brookfield Asset Management
Sunoco LP
NielsenIQ (NIQ)
Bausch + Lomb
Sanofi
Weil has successfully represented Sanofi in numerous transactions including, its ~$3.2 billion acquisition of Provention Bio, Inc., the maker of TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes and its $2.2 billion acquisition of Inhibrx, Inc., a publicly traded clinical-stage biopharmaceutical company.
NJOY
Global Infrastructure Partners
Lactalis Groupe
Giant Eagle
ChampionX
TPG Capital
Eutelsat
Nets A/S and Nexi SpA
Key Contacts



